Steroid-Cationic Lipid LNP for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cationic liposomes face safety concerns and low transfection efficiency due to nonspecific adsorption with serum proteins, leading to reduced circulation and stability, necessitating improved components and structures for safer and more effective delivery systems.
Innovation Solution
A cationic lipid compound with specific structural modifications, including naturally occurring or non-naturally occurring steroid groups, is formulated to enhance biocompatibility, stability, and transfection efficiency, combined with LNPs containing PEG-lipids and other lipids in optimized ratios for controlled particle size and uniform distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic liposomes are used for RNA drug delivery, then transfection efficiency is improved, but safety concerns arise due to nonspecific adsorption with serum proteins
Solution Approach 1:
The patent applies local quality by introducing PEGylated lipids at specific locations on the liposome surface (outer leaflet) to create regions with different properties: the PEGylated regions provide steric protection against protein adsorption, while the cationic lipid regions maintain transfection efficiency. This spatial differentiation resolves the contradiction between transfection efficiency and nonspecific adsorption.
Solution Approach 2:
The patent uses composite materials by combining multiple lipid types (cationic lipids, PEGylated lipids, and helper lipids) in a single liposome structure. This composite approach allows the system to simultaneously achieve high transfection efficiency (from cationic lipids) and reduced protein adsorption (from PEGylated lipids), resolving the technical contradiction.
2Productivity
If cationic liposomes are used for gene delivery, then transfection capability is enhanced, but circulation ability deteriorates due to formation of large-size agglomerates
Solution Approach 1:
The patent employs a flexible thin film structure by incorporating PEGylated lipids that form a flexible protective layer on the liposome surface. This flexible shell prevents rigid agglomerate formation while maintaining small particle size, thereby improving circulation ability without sacrificing transfection capability.
Solution Approach 2:
The patent applies parameter changes by optimizing the molecular weight and density of PEG chains, as well as the ratio of different lipid components. These parameter adjustments control the liposome's hydrodynamic radius and surface properties, preventing agglomeration and enhancing circulation stability while preserving transfection efficiency.
3Reliability
If modified cationic lipids are prepared into LNP delivery system, then safety and stability are improved, but transfection efficiency needs further enhancement
Solution Approach 1:
The patent merges multiple functional lipid components into a single LNP formulation: cationic lipids for transfection, PEGylated lipids for stability and safety, and helper lipids for structural integrity. This merging allows the system to achieve both high reliability (safety and stability) and high productivity (transfection efficiency) simultaneously.
Solution Approach 2:
The patent applies universality by designing an LNP formulation where each lipid component performs multiple functions: PEGylated lipids provide both steric protection and surface stabilization, while cationic lipids contribute to both complexation with RNA and membrane disruption for transfection. This multi-functionality resolves the contradiction between reliability and productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic lipid compound achieves high in vivo mRNA transfection efficiency, low biotoxicity, and stability, with enhanced encapsulation and specific immune responses, demonstrating improved safety and efficacy in delivering bioactive substances.
Implementation Method 1
Cationic liposome is a non-viral vector with a cell-like structure and biofilm properties, which can form a stable complex with RNA drugs having electronegativity by its electropositivity
Implementation Method 2
The LNP prepared from the cationic lipid compound of the present invention has safety and efficacy, good biocompatibility, high in vivo mRNA transfection efficiency, high stability
Data Source
Figure 1
Figure 2a~2b
Figure 2c~2d
AI summary
A steroid-cationic lipid compound as represented by formula (I). The LNP prepared from the compound can deliver a bioactive substance to a target cell or organ in an effective and stable manner, and the mRNA LNP prepared from the compound has good levels of stability and transfection efficiency, and can trigger a relatively high specific antibody response and cellular immune response in an animal.